BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neovasculgen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Neovasculgen\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07391319-1220@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Neovasculgen: Phase 3 readout est. (NCT07391319)
DESCRIPTION:Neovasculgen\, phase 3.\nStudy: The Prospective\, Double-blind\
 , Multicenter\, Placebo-controlled\, Randomized\, Comparative Clinical Tri
 al\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/neovasculgen#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07391319
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473740-1220@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Neovasculgen: Phase 4 readout est. (NCT06473740)
DESCRIPTION:Neovasculgen\, phase 4.\nStudy: The Endovascular Plus GENe Ther
 apy Versus Only EndoVascular Therapy for Severe Limb ischaemiA Trial\nEsti
 mated primary completion: 19 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/neovasculgen#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06473740
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391306-1220@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Neovasculgen: Phase 2/3 readout est. (NCT07391306)
DESCRIPTION:Neovasculgen\, phase 2/3.\nStudy: The Study is Being Conducted 
 to Find a New Treatment for Patients Suffering From Interstitial Cystitis 
 Without Hunner's Lesions.\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/neovasculgen#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07391306
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459790-1220@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Neovasculgen: Phase 2/3 readout est. (NCT07459790)
DESCRIPTION:Neovasculgen\, phase 2/3.\nStudy: The Study is Being Conducted 
 to Find a New Treatment for Patients Suffering From Interstitial Cystitis 
 With Hunner's Lesions\nEstimated primary completion: 30 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/neovasculgen#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07459790
URL:https://assetmemo.bio/drug/neovasculgen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
